User login
Key clinical point: Nanoparticle albumin-bound (nab) paclitaxel showed a superior pathological complete response (pCR) rate but similar disease-free survival (DFS) compared with docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC).
Major finding: Rate of pCR was significantly higher in the nab-paclitaxel vs. docetaxel group (36.71% vs. 20.00%; P = .031); however, DFS was not significantly different (P = .331). At least 1 drug-related adverse event was reported in 94.94% vs. 95.00% patients in the nab-paclitaxel vs. docetaxel group.
Study details: Findings are from a retrospective analysis of 159 patients with HER2-negative invasive BC who underwent surgery after receiving nab-paclitaxel (n = 79) or docetaxel (n = 80), both with epirubicin and cyclophosphamide.
Disclosures: This study was funded by the Postdoctoral Science Foundation of China, Natural Science Foundation of Shandong Province, and others. The authors declared no conflicts of interest.
Source: Lv Z-D et al. Front Oncol. 2022 (Jan 11). Doi: 10.3389/fonc.2021.760655.
Key clinical point: Nanoparticle albumin-bound (nab) paclitaxel showed a superior pathological complete response (pCR) rate but similar disease-free survival (DFS) compared with docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC).
Major finding: Rate of pCR was significantly higher in the nab-paclitaxel vs. docetaxel group (36.71% vs. 20.00%; P = .031); however, DFS was not significantly different (P = .331). At least 1 drug-related adverse event was reported in 94.94% vs. 95.00% patients in the nab-paclitaxel vs. docetaxel group.
Study details: Findings are from a retrospective analysis of 159 patients with HER2-negative invasive BC who underwent surgery after receiving nab-paclitaxel (n = 79) or docetaxel (n = 80), both with epirubicin and cyclophosphamide.
Disclosures: This study was funded by the Postdoctoral Science Foundation of China, Natural Science Foundation of Shandong Province, and others. The authors declared no conflicts of interest.
Source: Lv Z-D et al. Front Oncol. 2022 (Jan 11). Doi: 10.3389/fonc.2021.760655.
Key clinical point: Nanoparticle albumin-bound (nab) paclitaxel showed a superior pathological complete response (pCR) rate but similar disease-free survival (DFS) compared with docetaxel in patients with human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC).
Major finding: Rate of pCR was significantly higher in the nab-paclitaxel vs. docetaxel group (36.71% vs. 20.00%; P = .031); however, DFS was not significantly different (P = .331). At least 1 drug-related adverse event was reported in 94.94% vs. 95.00% patients in the nab-paclitaxel vs. docetaxel group.
Study details: Findings are from a retrospective analysis of 159 patients with HER2-negative invasive BC who underwent surgery after receiving nab-paclitaxel (n = 79) or docetaxel (n = 80), both with epirubicin and cyclophosphamide.
Disclosures: This study was funded by the Postdoctoral Science Foundation of China, Natural Science Foundation of Shandong Province, and others. The authors declared no conflicts of interest.
Source: Lv Z-D et al. Front Oncol. 2022 (Jan 11). Doi: 10.3389/fonc.2021.760655.